Jewish General Hospital Segal Cancer Centre
BREAST CLINIC

DESTINY Breast11: A Phase 3 open-label trial of neoadjuvant Trastuzumab Deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with high-risk
HER2-positive early-stage breast cancer 

ProHer: A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (closed to accrual)

COMPASS-HER2-RD: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

KEYNOTE 756: Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (closed to accrual)      

NRG-BR009 The OFSET Study: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression and Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score of ≤ 25 

EMBER-4: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

LALEAST: Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer. Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis (closed to accrual)

ELEGANT: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (opening soon)

DESTINY-Breast05 / NSABP B-60: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (closed to accrual)

MK-2870-012: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR

TROPION-Breast03: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy

OPTIMICE: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

TROPION-Breast04: A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

TRICIA: TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence

TADEN: Sentinel Node Biopsy and Targeted Axillary Dissection in Node Positive Breast Cancer Patients with Clinically Negative Axilla

TAXIS: Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

ROSALIE: Radiation Omission in Patients with Clinically Node Negative Breast Cancer Undergoing Lumpectomy and with a PathologIc Complete Response after Neoadjuvant Chemotherapy

Tailor RT (MA 39): A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

EXActDNA-003 /​ NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

CHARM: Cell-free DNA in Hereditary And High-Risk Malignancies (closed to accrual)